rituximab subcutaneous / Seelos Therap - LARVOL DELTA

High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab. (PubMed) - "These findings suggest that dual targeting with (177)Lu-based CD22-specific RIT in combination with rituximab is a promising new treatment option for refractory B-NHL."

Journal • Biosimilar • Diabetes • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Obesity • Oncology

Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration. (PubMed) - "This article is protected by copyright. All rights reserved."

Journal • Biosimilar • Hematological Malignancies

Administrative risk quantification of subcutaneous and intravenous therapies in Italian centers utilizing the Failure Mode and Effects Analysis approach. (PubMed) - Clinicoecon Outcomes Res - "The subcutaneous administration of trastuzumab (breast cancer) and rituximab (hematology) might lower the risk of administration and treatment errors for patients and could hence indirectly have a positive financial impact for hospitals."

Journal • Biosimilar • Breast Cancer • Oncology

Safety And Insurance Premium Implications For Hospitals Based On Subcutaneous Versus Intravenous Administration Of Oncology / Hematology Therapies: Case Studies With Rituximab (Mabthera) And Trastuzumab (Herceptin). (PubMed) - Value Health - No abstract available.

Journal • Biosimilar

Rituximab for subcutaneous delivery: Clinical management principles from a nursing perspective. (PubMed) - Int J Nurs Pract - "Compared with IV, SC delivery reduces treatment times and nurse workload, and patients report greater comfort and convenience. This article sets out nursing considerations for optimal administration of SC rituximab, including premedication, drug handling/preparation, injection technique, after-care and management of adverse events, particularly administration-related reactions."

Journal • Biosimilar • Non-Hodgkin’s Lymphoma • Oncology

Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment (clinicaltrials.gov) - P2; N=35; Active, not recruiting; Sponsor: Institut Paoli-Calmettes; Recruiting -> Active, not recruiting

Enrollment closed • Biosimilar • Hematological Malignancies • Leukemia • Non-Hodgkin’s Lymphoma • Oncology

This Trial is a Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma (clinicaltrials.gov) - P2; N=112; Recruiting; Sponsor: International Extranodal Lymphoma Study Group (IELSG); Not yet recruiting -> Recruiting

Enrollment open • Biosimilar • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

Effectiveness, Safety & Nurse Management Study of MabThera SC in Patients With Non-Hodgkin's Lymphoma: Real-Life Setting (clinicaltrials.gov) - P=N/A; N=100; Recruiting; Sponsor: Hoffmann-La Roche; Not yet recruiting -> Recruiting

Enrollment open • Biosimilar • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology